Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials

Objectives: To investigate the effect of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer in terms of pCR and cardiotoxicity. Methods: We systematically searched Pubmed, Embase, Cochrane and SinoMed databases from inception unti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Autores principales: Wu, Yu-tuan, Xu, Zhou, Arshad, Bilal, Wu, Jiu-song, Zhang, Ke, Wu, He, Li, Xin, Li, Hao, Li, Ying-cun, Wang, Zhong-liang, Wu, Kai-nan, Kong, Ling-quan
Formato: Artigo
Lenguaje:Inglês
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6134822/
https://ncbi.nlm.nih.gov/pubmed/30210640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.24701
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares